Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: Population-based study
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background: Late-gestational serotonin reuptake inhibitor (SRI) exposure has been linked to adverse neonatal outcomes; however, the impact of timing and duration of exposure is unknown. Aims: To determine whether late-gestational exposure to an SRI is associated with increased risk of adverse neonatal outcome relative to early exposure. Method: Population-based maternal and neonatal health records were linked to prenatal maternal prescription records for an SRI medication (n=3500). Results: After controlling for maternal illness and duration of exposure, using propensity score matching, neonatal outcomes did not differ between late and early exposure (P IQ>0.05). After controlling for maternal illness, longer prenatal exposure increased the risks of lower birth weight, respiratory distress and reduced gestational age (P<0.05). Conclusions: Using population health data, length of gestational SRI exposure, rather than timing, increased the risk for neonatal respiratory distress, lower birth weight and reduced gestational age, even when controlling for maternal illness and medication dose. These findings highlight the importance of distinguishing the specific impact of medication exposure from exposure to maternal illness itself.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Serotonin as a developmental signal
Whitaker-Azmitia, P. M., Druse, M., Walker, P., & Lauder, J. M. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00071-x · Cited by 356
Cited by
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Antidepressant Use During Pregnancy and Childhood Autism Spectrum Disorders
Croen, L. A. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.73 · Cited by 510
Yonkers, K. A., Wisner, K. L., Stewart, D. E., Oberlander, T. F., Dell, D. L., Stotland, N., Ramin, S., Chaudron, L., & Lockwood, C. (2009) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2009.04.003 · Cited by 469
Self-citation(2009) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3181ba0632 · Cited by 345
Reis, M., & Källén, B. (2010) · Psychological Medicine · doi:10.1017/s0033291709992194 · Cited by 340
Statement on Pregnancy in Pulmonary Hypertension from the Pulmonary Vascular Research Institute
Hemnes, A. R., Kiely, D. G., Cockrill, B. A., Safdar, Z., Wilson, V. J., Hazmi, M. A., Preston, I. R., MacLean, M. R., & Lahm, T. (2015) · Pulmonary Circulation · doi:10.1086/682230 · Cited by 334
Depression during pregnancy and postpartum
Becker, M., Weinberger, T., Chandy, A., & Schmukler, S. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-016-0664-7 · Cited by 263
Huang, H., Coleman, S., Bridge, J. A., Yonkers, K., & Katon, W. (2014) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2013.08.002 · Cited by 180
Antidepressant use in pregnancy: a critical review focused on risks and controversies
Byatt, N., Deligiannidis, K. M., & Freeman, M. P. (2013) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12042 · Cited by 158
“It is not certain that SSRIs are associated with the development of PPHN, but there is some evidence that longer periods of in utero SSRI exposure may be associated with increasing risk, and severity, of neonatal respiratory complications (132).”
BackgroundMaternal antidepressant use and adverse outcomes: a cohort study of 228,876 pregnancies
Hayes, R. M., Wu, P., Shelton, R. C., Cooper, W. O., Dupont, W. D., Mitchel, E., & Hartert, T. V. (2012) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2012.04.028 · Cited by 149
Antidepressants in pregnancy: a systematic review.
(2010) · PubMed · doi:10.3109/00048674.2010.507543 · Cited by 128
“…depressed and control p 0.001 Wen et al., 2006 [44] Retrospective cohort SSRIs n 972 Controls n 3878 Birth weight 2500 g OR 1.58 (95%CI 1.19–2.1) Oberlander et al., 2008 [65] Prospective case-control SSRIs n 3500 Low birth weight related to length of exposure p 0.05 Lattimore et al., 2005…”
BackgroundInfluentialCalderon-Margalit, R., Qiu, C., Ornoy, A., Siscovick, D. S., & Williams, M. A. (2009) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2009.06.061 · Cited by 115
The use of psychotropic medication during pregnancy: how about the newborn?
Kieviet, N., Honig, & Dolman (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s36394 · Cited by 100
Tuccori, M., Testi, A., Antonioli, L., Fornai, M., Montagnani, S., Ghisu, N., Colucci, R., Corona, T., Blandizzi, C., & Tacca, M. D. (2009) · Clinical Therapeutics · doi:10.1016/j.clinthera.2009.07.009 · Cited by 95
Neonatal S100B Protein Levels After Prenatal Exposure to Selective Serotonin Reuptake Inhibitors
Pawluski, J. L., Galea, L. A. M., Brain, U., Papsdorf, M., & Oberlander, T. F. (2009) · Pediatrics · doi:10.1542/peds.2009-0442 · Cited by 65
Self-citationDrug treatment for mood disorders in pregnancy
Gentile, S. (2011) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e3283413451 · Cited by 60
Tak, C. R., Job, K. M., Schoen-Gentry, K., Campbell, S. C., Carroll, P., Costantine, M., Brixner, D., Birnbaum, A. K., & Sherwin, C. M. T. (2017) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-017-2269-4 · Cited by 27
Metadata
- Authors
- Oberlander, T. F., Warburton, W., Misri, S., Aghajanian, J., & Hertzman, C.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2008-05
- Volume
- 192
- Issue
- 5
- Pages
- 338-343
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2122520702
- Cited by
- 131
- References
- 1
- FWCI
- 15.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.